A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia - Wikidata - awgldk - TriplyDB

A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia

A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia

http://www.wikidata.org/entity/Q34414748

about

Advances in antibiotic therapy in the critically ill Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient Pseudomonas aeruginosa ventilator-associated pneumonia management Ceftobiprole for the treatment of pneumonia: a European perspective Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship.Antibiotics for ventilator-associated pneumonia.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy.Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole.Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice.Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.The time-dependent "cure-death" model investigating two equally important endpoints simultaneously in trials treating high-risk patients with resistant pathogens.Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?Emerging drugs for nosocomial pneumonia.Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.New horizons in hospital acquired pneumonia in older people.[New antibiotics - standstill or progress].Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges.[Severe pneumonia in the intensive care unit].[New antibacterial agents on the market and in the pipeline].Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.Assessing Noninferiority in Treatment Trials for Severe Infectious Diseases: an Extension to the Entire Follow-Up Period Using a Cure-Death Multistate Model.Editorial Commentary: Antimicrobial De-escalation: What's in a Name?Linezolid: a review of its properties, function, and use in critical care.Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015

P2860

Q26749328-AE8DDE43-1D1D-42C3-A358-CCB1E45EEFF7 Q26752680-F32584BA-9083-4BBA-9F68-1B2A101F5990 Q26768365-AE57386E-BF5D-472B-85DD-3B5B8C3F743E Q26796463-652EBFAA-C9C2-4B08-94DC-4C47B84405EC Q28066877-0C01FBD4-1011-4A0E-8A44-4747442E016C Q28071882-5CE6BC48-3ABE-4421-9E36-C8A7AECF4037 Q28085517-DA510AA8-552D-4663-8DE0-D157A4AB49B9 Q30238578-2E6F06D6-0B61-40EE-B3E7-5857E1666AAA Q30243877-BA84335E-E33C-403B-8302-91834491AB93 Q33429168-CB262A00-0AC9-425B-812A-A4D033FF4301 Q33822682-152FE621-1118-4AB2-8D3C-44381A971C35 Q34433342-E56546BB-99DC-40A9-8B05-26855E4C9434 Q35542062-57FEF067-A052-4E2B-82BA-D9CE305AEB21 Q36078359-5D886AFE-B420-4364-BE4A-571E47373896 Q36355345-FF8EE291-9066-4D4C-9C46-17787BC9AF18 Q36489501-4A407822-7B97-4A3C-B0B5-7770C2C46BBD Q38462842-E8856743-FE42-454B-8E9B-45E69D9AE7F4 Q38468392-A1EFF00B-DD42-404A-B559-6A7E9394967E Q38672879-D49091DF-105A-4CDA-A2FB-9E1A21885E85 Q38835029-49DC3C56-3144-402C-B47A-F89A8E003356 Q38878167-E8AFFCC4-0770-4484-BE17-3E8DD67338F7 Q39164183-6CA8803D-190D-4ABE-AB64-5B51EF0471EF Q40279983-02E2AFE8-C729-4C2C-8AFC-2E4EDA111C08 Q40289701-57907215-0603-4C42-B75B-31655EDE98CA Q40422166-1A0CE259-E099-4518-B10F-78C22C37172E Q40763182-8871ABD1-51B7-43DA-A336-B8AA3980A6E9 Q40948209-64525A93-D476-4D55-B012-0B5F37C1DCEB Q41695620-51DE1566-D44C-4040-9728-25BA9D662379 Q47634145-70A645A3-850E-4CDB-8F24-1B7F8B819857 Q48143379-36BD24F4-3F15-451A-A211-CEB9E7D15BA2 Q53804008-2A845867-53C6-4B32-90E2-2DC68F5CE750 Q55368160-A8141778-196E-44BE-A792-B5AFE03E773C Q56835140-F622D3A3-A845-4C16-B971-2FDB79440E34

P2860

A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia

http://www.wikidata.org/entity/Q34414748

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase 3 randomized double-bl ...... of hospital-acquired pneumonia

@ast

A phase 3 randomized double-bl ...... of hospital-acquired pneumonia

@en

A phase 3 randomized double-bl ...... of hospital-acquired pneumonia

@nl

type

label

A phase 3 randomized double-bl ...... of hospital-acquired pneumonia

@ast

A phase 3 randomized double-bl ...... of hospital-acquired pneumonia

@en

A phase 3 randomized double-bl ...... of hospital-acquired pneumonia

@nl

prefLabel

A phase 3 randomized double-bl ...... of hospital-acquired pneumonia

@ast

A phase 3 randomized double-bl ...... of hospital-acquired pneumonia

@en

A phase 3 randomized double-bl ...... of hospital-acquired pneumonia

@nl

P1433

Q34414748-B1B35ED5-1BFC-4C97-BA26-EE8176A212D9

P1476

Q34414748-36ACD86C-6EA9-4A00-8157-2801BAF0B459

P2093

Q34414748-30351BF6-E4E3-4C2E-B0F5-3C5297E4639E

Q34414748-44A70233-6D00-4F51-9967-0E2DFBCE9482

Q34414748-5E20311B-F4DA-45FC-A921-B63A2955D50E

Q34414748-67F15092-0CF6-42B4-B498-7841B19F1E08

Q34414748-E4A287BC-AFCD-407C-9D9D-CE9A222895EB

Q34414748-E637155E-062F-473D-A1B6-B0E10DB4F722

Q34414748-E78995EE-AF04-4E64-973E-3BAE624FCF3A

Q34414748-EF380249-A8FB-4CFB-A54A-DA269B16DEA0

Q34414748-F7EA5C68-42D3-40A4-9D8A-B342F02CF0A9

P2860

Q34414748-0064CC2C-EBA1-41E3-B205-8297C5237526

Q34414748-024360B5-7436-42A7-95B5-DC329C7DE281

Q34414748-0E019320-D799-44F8-957E-CE8892ABA8F2

Q34414748-1BB821F3-7432-4FC1-826B-F68669DC910E

Q34414748-1CFDA134-89F1-4A30-B534-C5F0298284D8

Q34414748-2A7F4D1A-4851-4F87-BFD7-C6441F8F2760

Q34414748-2DCC8791-B799-4B50-B9D9-2EA564093D09

Q34414748-447F7B89-F34F-4FFB-A33E-4D618426D05F

Q34414748-4695F064-21CD-4460-89BD-15B7028754FA

Q34414748-5418E6A8-705A-4E26-A0EB-3F7DC8D2BACE

P304

Q34414748-6F2C5425-FA1E-420F-BCD9-521AAFC8ECBB

P31

Q34414748-6F15F18A-455F-47DC-912E-F9027EC4526C

P356

Q34414748-325CE892-FEA5-487C-9585-E7D43086E3F7

P407

Q34414748-1B38F1E8-8BEC-4F89-912C-99F09AE5052C

P433

Q34414748-D495E4DB-874E-41F5-98A1-4FD2912D2FDF

P478

Q34414748-733160D7-6605-43CD-AA54-CEC68C368456

P50

Q34414748-77395296-1372-4DFC-8B37-B6ADAF9548D9

Q34414748-BC74ED6C-FEED-48C3-9D39-8E691256B38E

P577

Q34414748-F415031E-EBE9-40C3-90B1-7158E9143360

P5875

Q34414748-0A0B6A14-BBA5-4457-BD9F-B94772E81DA1

P698

Q34414748-D70E93E5-E35F-44C2-8A4C-A093F81EC707

P921

Q34414748-67792B3A-A9A7-47AD-BF9F-87C9A4797B1A

P932

Q34414748-BAEE8A74-74EB-4FB6-82C0-A8DB6015CB18

P356

P1433

Clinical Infectious Diseases

P1476

A phase 3 randomized double-bl ...... of hospital-acquired pneumonia

@en

P2093

Alejandro H Rodriguez

http://www.w3.org/2001/XMLSchema#string

Alejandro S Sánchez

http://www.w3.org/2001/XMLSchema#string

Alex J Pareigis

http://www.w3.org/2001/XMLSchema#string

Marc Engelhardt

http://www.w3.org/2001/XMLSchema#string

Mikaël Saulay

http://www.w3.org/2001/XMLSchema#string

Samir S Awad

http://www.w3.org/2001/XMLSchema#string

Xin Zhou

http://www.w3.org/2001/XMLSchema#string

Yin-Ching Chuang

http://www.w3.org/2001/XMLSchema#string

Zsuszanna Marjanek

http://www.w3.org/2001/XMLSchema#string

P2860

Structural Insights into the Anti-methicillin-resistant Staphylococcus aureus (MRSA) Activity of Ceftobiprole

In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.

A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.

Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.

Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.

In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals

Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits

Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study

The place of guidelines in hospital-acquired pneumonia.

P304

51-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIU219

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261604859

http://www.w3.org/2001/XMLSchema#string

P698

24723282

http://www.w3.org/2001/XMLSchema#string

P921

P932

4305133

http://www.w3.org/2001/XMLSchema#string